Despite the golf carts, scorecards and friendly competition, Shad’s R&R once again demonstrated that its true purpose extends far beyond the fairways.

Held for the 51st time, the Canadian aftermarket’s signature charitable event brought together participants from across North America for a day of camaraderie and fundraising. This year’s event raised more than $220,000, building on the cumulative total of more than $6 million set last year.

Under the chairship of Charlie Grant, the event featured a number of new elements such as digital scoring and a welcome streamlining of post golf clubhouse activities.

The real impact of the funds raised by Shad’s R&R was underscored by keynote speaker Dr. Homira Osman, who shared how decades of research funding have transformed outcomes for patients and families affected by neuromuscular diseases.

“About 20 years ago, if a child was diagnosed with any neuromuscular condition, the conversation with the physician and the family was devastatingly short,” Osman told attendees. Families naturally wanted to know whether treatments or cures existed, but “too often the answer from the physician would be none.”

At the time, doctors could offer little beyond symptom management and support. Today, however, the conversation has changed dramatically.

“Physicians talk about therapies, clinical trials, precision medicine, gene therapies, earlier diagnosis and newborn screening,” she said. “These possibilities would have seemed unimaginable not too long ago.”

Osman pointed to spinal muscular atrophy (SMA) as one of the clearest examples of that progress. Once the leading genetic cause of infant death, children diagnosed with SMA often faced a life expectancy of less than two years.

Today, newborn screening programs across Canada identify the condition within days of birth. Infants can be referred to specialists within weeks and begin treatment before symptoms appear.

“As a result, these children are sitting, walking, running, going to school and growing up with opportunities that simply didn’t exist a decade ago,” Osman said.

Importantly, she noted that Shad’s fundraising is helping drive the next generation of breakthroughs.

Osman highlighted research led by Dr. Rashmi Kothary in Ottawa that was directly funded through Shad’s research fund following last year’s event. The project is exploring whether treatment for SMA could begin even earlier — during pregnancy.

“His team is exploring what would almost seem unimaginable not too long ago,” she said. The research is investigating whether intervention before birth can better protect developing nerves and muscles and further improve outcomes for children diagnosed with SMA.

“I know exactly as someone who administered those funds that came directly from Shad’s research fund from last year,” Osman said. “So that’s extraordinary.”

The advancement illustrates how dramatically the field has evolved.

“A generation ago, we were asking whether treatment is possible,” she said. “Today researchers are asking whether treatment can happen before birth.”

Osman also shared the story of Danielle, Muscular Dystrophy Canada’s national ambassador, who lives with a rare form of SMA. When Danielle was diagnosed as a child, her family was effectively told there was little that could be done. Years later, after becoming a parent herself, she sought answers from leading specialists about the future of treatment.

“The question is no longer if there will be treatment,” Osman recalled being told. “The question is when.”

For Osman, that shift captures the significance of events such as Shad’s R&R.

“Today, thanks to Shad’s events and fundraising, we’re talking about treatments. We’re talking about getting closer to a cure,” she said.

As organizers continue their journey toward a long-term fundraising goal of $10 million, Osman left attendees with a simple message of gratitude.

“Thank you for believing in research,” she said. “Thank you for transforming possibility into progress.”